Stock Update (NASDAQ:GILD): U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

[Business Wire] – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Odefsey® for the treatment of HIV-1 infection in certain patients. Read more on this. Gilead Sciences Inc. (GILD) , with a current value of $127.54B, started the session at $87.90. Looking at today’s trading action, the company’s one day range from $87.30 to $89.72 with its 52-week range being $81.89 to $123.37. GILD shares are currently priced at 7.22x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.27x earnings multiple. And for those looking to make a return holding the stock, the company pays shareholders $1.72 per share annually in dividends, yielding 1.95%. According to a consensus of 21 analysts, the earnings estimate of $3.09 per share would be $0.15 better than the year-ago quarter and a $0.17 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $12.20 would be a $0.41 worse when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $7.98 Billion. If reported, that would be a 5.14% increase over the year-ago quarter. More recently, Citigroup Initiated GILD at Buy (Feb 25, 2016). Previously, Standpoint Research Initiated GILD at to Buy. When considering if perhaps the stock is under or overvalued, the average price target is $115.60, which is 31.51% above where the stock opened this morning. See more in (NASDAQ:GILD) Similar Articles: Stock Update (NASDAQ:GILD): European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B Market Update (NASDAQ:GILD): Health Canada Issues Notice of Compliance for Gilead’s Single Tablet Regimen Genvoya™ (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection